Effectiveness of integrated vector management on the incidence of dengue in urban Malaysia: a cluster-randomised controlled trial - 21/08/25
, Muriel Rabilloud, MD c, d, e, Tim W R Möhlmann, PhD f, Carole Langlois-Jacques, MSc c, d, e, Farah Diana Ariffin, MSc g, Marit Farenhorst, PhD f, Mad-Hélénie Elsensohn, MSc c, d, e, Frédéric Schmitt, PhD h, Jason H Richardson, PhD i, Frédéric Baur, MSc h, Maxime Leduc, MBA h, Nurul Nadia Romli, MSc g, Lay Kim Tan, PhD j, Mohd-Rosli Norazman, DrPH k, Hanipah Shahar, MSc l, Rose Nani Mudin, MD l, Neal Alexander, PhD m, Nurulhusna Ab Hamid, PhD gSummary |
Background |
Malaysia is one of the southeast Asian countries hardest hit by dengue. We implemented a proactive integrated vector management (IVM) approach in a large non-blinded, cluster-randomised controlled trial to quantify its effectiveness on dengue incidence in urban settings.
Methods |
In this cluster-randomised controlled trial we enrolled low-cost and medium-cost residential housing blocks in the Federal Territory of Kuala Lumpur and Putrajaya with recurrent dengue outbreaks. Of the 329 eligible sites, 139 were randomly allocated to receive IVM measures (community engagement, targeted outdoor residual spraying using K-Othrine Polyzone, and deployment of autodissemination devices to target both larval and adult mosquitoes) and 141 received routine vector control activities, stratified by block housing cost. The primary outcome was the comparison of dengue incidence between the two groups using information provided by the national e-Dengue surveillance system. Routine vector control activities continued in both control and intervention sites. The trial was retrospectively registered (ISRCTN81915073).
Findings |
Between Feb 10, 2020, and Sept 30, 2022, we carried out our IVM approach in the 139 randomly selected intervention sites. 903 834 individuals (447 149 intervention, 456 685 control) were living in the study areas. Dengue was reported in 1434 individuals in the intervention group (mean incidence per 100 person-years of 0·16 [SD 0·18]) compared with 1663 in the control group (0·18 [0·19; risk ratio 0·86, 95% CI 0·70–1·06; p=0·17). No adverse effects were reported.
Interpretation |
Our study did not show an effect on the primary endpoint of the overall dengue incidence. Several factors such as substantial decrease in dengue incidence during the COVID-19 pandemic could have reduced the statistical power to detect significant differences between the two groups. Preventive and long-lasting approaches such as our IVM should be further tested to see if targeted interventions could help limit the number of cases in high-risk transmission areas.
Funding |
Ministry of Health Malaysia, Fondation Innovation en Infectiologie, the Australian Government, UK International Development from the UK Government, Envu.
Translation |
For the Malay translation of the abstract see Supplementary Materials section.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 9
P. 977-985 - septembre 2025 Retour au numéro
Article précédent
- Safety and efficacy of single-dose primaquine to interrupt Plasmodium falciparum malaria transmission in children compared with adults: a systematic review and individual patient data meta-analysis
- Daniel Yilma, Kasia Stepniewska, Teun Bousema, Chris Drakeley, Prashanti Eachempati, Philippe J Guerin, Andreas Mårtensson, Richard Mwaiswelo, Walter R Taylor, Karen I Barnes, WWARN Paediatric Primaquine for P falciparum Transmission Blocking Study Group, Elizabeth N Allen, Eliana Arango, Karen I. Barnes, Guido J.H. Bastiaens, Teun Bousema, Joelle Brown, Rutuja Chhajed, Robert J. Commons, Umberto D’Alessandro, Nicholas PJ Day, Mehul Dhorda, Alassane Dicko, Arjen Dondorp, Chris Drakeley, Lek Dysoley, Prashanti Eachempati, Badria El-Sayed, Salah-Eldin El-Zaki, Alice C Eziefula, Roly Gosling, Philippe J Guerin, Gordon Guyatt, Muzamil M. Abdel Hamid, Eli Harriss, Wasif Ali Khan, Titus K Kwambai, Benedikt Ley, Andreas Mårtensson, Lwidiko E. Mhamilawa, Dominic Mosha, Richard Mwaiswelo, Billy Ngasala, Roland Ngu, Joseph Okebe, Eugenie Poirot, Ric N Price, Sumayyah Rashan, Caitlin Richmond, Aaron M Samuels, Farhad Shokraneh, Frank Smithuis, Kasia Stepniewska, William Stone, Inge Sutanto, Walter R Taylor, Feiko ter Kuile, Kamala Thriemer, Kyaw Myo Tun, Alfred B Tiono, Rob W van der Pluijm, Amelie Vantaux, Nicholas J White, Daniel Yilma
- Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial
- Laura Wagner, Michaela Obersriebnig, Vera Kadlecek, Romana Hochreiter, Santhosh Kumar Ghadge, Julian Larcher-Senn, Lisa Hegele, Jason D Maguire, Ulla Derhaschnig, Juan Carlos Jaramillo, Susanne Eder-Lingelbach, Nicole Bézay
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?